EATONTOWN, N.J., May 21 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Nasdaq: RPCX) today announced that Mr. Joseph N. Noonburg and the Honorable
Marilyn Lloyd have joined its Board of Directors.  Mr. Noonburg, a self-
employed consultant, has a 38-year background in the pharmaceutical industry.
Ms. Lloyd, a former Congresswoman, is a consultant for Lockheed Martin
Corporation and the Spectrum Group and serves on a number of boards including
the board of Lockheed Martin Energy Research Corporation.
    Commenting on the announcement, Dr. Robert A. Vukovich, Chairman and CEO
of Roberts, said "We are fortunate to have individuals with the breadth of
experience of Marilyn Lloyd and Joe Noonburg.  We recently began
commercializing our proprietary product pipeline and Marilyn's experience with
the FDA and Joe's industry background will be invaluable assets as we enter
this exciting growth phase.  We are also gratified by the confidence
Yamanouchi Group Holding, our largest shareholder, has expressed in Roberts."
Yamanouchi previously held two seats on Roberts Board and, under the terms of
a stock purchase agreement, Yamanouchi is now entitled to designate only one
member of the board for election.  Yamanouchi has noted its continued interest
in Roberts future and, while not designating a nominee to Roberts Board at
this time, retains the right to do so at a future date.
    Mr. Noonburg was elected at Roberts' Annual Meeting of Shareholders held
today at the Company's headquarters in Eatontown.   In addition, Messrs. Loy,
Spitznagel, Rogalin, Rascio, Barrios, and Horovitz were re-elected as members
of the Board of Directors and Dr. Vukovich was re-elected Chairman.  Following
the Annual Shareholders' Meeting, the newly elected Board of Directors
convened and appointed Ms. Lloyd as a director, restoring the Board to nine
members.
    From 1974 through 1995, Ms Lloyd represented Tennessee's Third
Congressional District in the U.S. House of Representatives.  In addition to
being Chairman of the Energy Subcommittee of the House Science and Technology
Committee, she championed many initiatives promoting health care awareness for
women and chaired the Housing and Consumer Committee of the Committee on
Aging.  In addition to her corporate board positions, Ms. Lloyd is a member of
Secretary Pena's Energy Advisory Board.
    Mr. Noonburg is former Senior Vice President, Sales for the pharmaceutical
firm of Reed & Carnick and General Manager of Strafford Miller, Reed &
Carnick's generic drug division. During his 38-year career in the
pharmaceutical industry, Mr. Noonburg has been actively involved in several
pharmaceutical industry associations including, the Pharmaceutical Research
and Manufacturers Association, National Wholesale Druggist Association and the
National Association of Chain Drug Stores.
    Roberts Pharmaceutical Corporation, with operating subsidiaries in the
U.S., Canada, and the United Kingdom, focuses on new health care solutions
through the acquisition and development of specialty pharmaceuticals.  The
Company's first proprietary product, ProAmatine(R) was recently launched in
the U.S. as the first drug indicated for treating orthostatic hypotension.
Agrylin(TM), now being launched in the U.S. as first drug indicated for
treating essential thrombocythemia, has been given priority review status in
Canada and should be filed this year for approval in Europe.
    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action and competing products.
Any changes in such assumptions or external factors could produce
significantly different results.

Link to this page: